多嚢胞性卵巣症候群（PCOS）治療市場：薬剤クラス別、流通チャネル別、地域別

多嚢胞性卵巣症候群（PCOS）治療市場は、2025年に11億9,520万米ドルと予測され、2032年には16億6,610万米ドルに達する見込みで、2025年から2032年までのCAGRで4.86％の成長が予測されています。

多嚢胞性卵巣症候群（PCOS）は、内分泌系疾患の結果として卵巣に液体で満たされた小さな袋ができる病気です。出産適齢期のPCOS女性が罹患します。PCOS陽性女性は、流産、妊娠糖尿病、妊娠高血圧症候群、子癇前症、早産を経験しやすいです。さらに、PCOSの女性は、月経不順、アンドロゲン（性ホルモン）レベルの上昇、過剰な発毛、にきび、肥満を経験することがあります。

PCOSの女性は、深刻な健康問題を発症する可能性が高いです。これには、2型糖尿病、高血圧、心臓や血管の問題、子宮がんなどが含まれます。PCOSに罹患している女性は、妊娠するのに苦労すること（不妊）が多いです。

市場力学

経口避妊薬の効果的な使用と製品価値の増加が、予測期間中の多嚢胞性卵巣症候群（PCOS）治療市場を牽引する可能性があります。例えば、2022年8月にNCBIに論文が掲載され、それによると、PCOSの治療において、経口避妊薬（OC）の主な作用機序は月経をコントロールすることです。また、これらの薬剤はテストステロンレベルを低下させることにより、多毛症やニキビを減少させます。したがって、経口避妊薬は多嚢胞性卵巣症候群（PCOS）の主要な治療薬です。

さらに、多嚢胞性卵巣症候群（PCOS）治療における新しいメカニズムに対する認識の高まりが、予測期間中の市場の成長を後押しすると予想されています。例えば、中国の産婦人科が2020年11月に発表した研究によると、電気鍼（EA）の介入は、脂質代謝の調節因子であるSREBP1の調節を通じてIR、ミトコンドリア機能不全、酸化ストレスを改善することで、ラットのPCOS様症状が緩和されたことが示されています。この研究結果は、PCOS治療におけるEAの新たな保護メカニズムを明らかにするものです。

本研究の主な特徴

• 本レポートは、世界の多嚢胞性卵巣症候群（PCOS）治療市場を詳細に分析し、2024年を基準年とした予測期間2025-2032年の市場規模および年間平均成長率（CAGR%）を提供しています。
• さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案のマトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界の多嚢胞性卵巣症候群（PCOS）治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 世界の多嚢胞性卵巣症候群（PCOS）治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
• 利害関係者は、世界の多嚢胞性卵巣症候群（PCOS）治療市場の分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場の魅力分析
  • 市場機会
• 疫学
• 規制シナリオ
• 製品の発売
• 合併、買収、提携
• 主な発展
• 市場動向
• PEST分析
• ポーターの分析
• リスクと副作用
• 主要市場プレーヤーによる新規投資
• パイプライン分析
• サプライチェーン分析
• 価格分析
• ブランド分析

第4章 世界の多嚢胞性卵巣症候群（PCOS）治療市場 - コロナウイルス（COVID-19）パンデミックの影響

• 経済への影響
• COVID-19疫学
• 臨床試験への影響

第5章 世界の多嚢胞性卵巣症候群（PCOS）治療市場、薬剤クラス別、2020年～2032年

• 経口避妊薬
• インスリン抵抗性改善薬
• 抗うつ薬
• オルニチン脱炭酸酵素阻害剤
• アロマターゼ阻害剤・SERM
• 利尿剤

第6章 世界の多嚢胞性卵巣症候群（PCOS）治療市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の多嚢胞性卵巣症候群（PCOS）治療市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• 中東
  • GCC
  • イスラエル
  • その他中東
• アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第8章 競合情勢

• Sanofi S.A.
• Amneal Pharmaceuticals, Inc.
• Laurus Labs Limited
• Zydus Pharmaceuticals, Inc.
• Prasco Laboratories
• Reddy's Laboratories
• Cadila Pharmaceuticals
• Novartis International AG
• Concordia Pharmaceuticals Inc.
• Covis Pharmaceuticals, Inc.
• Cardinal Health
• Aphena Pharma Solutions Tennessee, Inc.
• Mylan N.V.
• McKesson Corporation
• Teva Pharmaceutical Industries Ltd
• Lupin Pharmaceutical
• Sun Pharmaceutical Industries Ltd.

第9章 セクション

• 調査手法
• 出版社について

Polycystic Ovary Syndrome (PCOS) Treatment Market is expected to be USD 1,195.2 Mn in 2025 and is anticipated to reach USD 1,666.1 Mn in 2032 at a compound annual growth rate (CAGR) of 4.86% for the forecast period of 2025 to 2032

Polycystic Ovarian Syndrome (PCOS) can be described as small sacs filled with fluid develop on the ovaries as a result of the endocrine system condition. Women with PCOS who are of childbearing age are affected. PCOS-positive women are more likely to experience miscarriage, gestational diabetes, pregnancy-induced hypertension, preeclampsia, and early birth. Moreover, women with PCOS may experience irregular menstrual cycles, elevated androgen (sex hormone) levels, excessive hair growth, acne, and obesity.

Women who have PCOS are more likely to develop serious health issues. These include type 2 diabetes, high blood pressure, heart and blood vessel problems, and uterine cancer. Women suffering from PCOS frequently struggle to conceive (fertility).

Market Dynamics

Effective use of oral contraceptives and increasing product value can drive the polycystic ovary syndrome (PCOS) treatment market over the forecast period. For instance, in August 2022, an article was published in the NCBI, according to which, for the treatment of PCOS, the major mechanism of action of oral contraceptives (OCs) is to control menstruation. These drugs also reduce hirsutism and acne by lowering testosterone levels. Thus, oral contraceptives are primary treatment for the polycystic ovary syndrome.

Moreover, rising awareness about novel mechanisms in the treatment of Polycystic Ovary Syndrome (PCOS) is anticipated to boost the growth of the market over the forecast period. For instance, according to research study published by Department of Obstetrics and Gynecology, China in November 2020, stated that the electroacupuncture (EA) intervention alleviated PCOS-like symptoms in rats by improving IR, mitochondrial dysfunction and oxidative stress through regulation of SREBP1, a regulator of lipid metabolism. The study findings illuminate the novel protective mechanisms of EA in the treatment of PCOS.

Key features of the study:

• This report provides in-depth analysis of the global Polycystic Ovary Syndrome (PCOS) Treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global Polycystic Ovary Syndrome (PCOS) Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Polycystic Ovary Syndrome (PCOS) Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Polycystic Ovary Syndrome (PCOS) Treatment Market

Market Segmentation

• By Drug Class
  • Oral contraceptives
  • Insulin Sensitizing Agents
  • Anti-Depressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Sanofi S.A.
  • Amneal Pharmaceuticals, Inc.
  • Laurus Labs Limited
  • Zydus Pharmaceuticals, Inc.
  • Prasco Laboratories
  • Reddy's Laboratories
  • Cadila Pharmaceuticals
  • Novartis International AG
  • Concordia Pharmaceuticals Inc.
  • Covis Pharmaceuticals, Inc.
  • Cardinal Health
  • Aphena Pharma Solutions Tennessee, Inc.
  • Mylan N.V.
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin Pharmaceutical
  • Sun Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
• Epidemiology
• Regulatory Scenario
• Product Launches
• Merger, Acquisition, Collaborations
• Key Developments
• Market Trends
• PEST Analysis
• PORTER'S Analysis
• Risk and Adverse Effects
• New Investments by Major Market Players
• Pipeline Analysis
• Supply Chain Analysis
• Pricing Analysis
• Brand Analysis

4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Clinical Trials

5. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral contraceptives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Insulin Sensitizing Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Anti- Depressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Ornithine Decarboxylase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Aromatase Inhibitors & SERMs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Distribution Channel, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Region, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amneal Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Laurus Labs Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Zydus Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prasco Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Concordia Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Covis Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cardinal Health
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aphena Pharma Solutions Tennessee, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• McKesson Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us